Gastroenterology Prior Authorization Automation

High-Volume Prior Authorization Categories in Gastroenterology

Gastroenterology practices face a substantial prior authorization burden driven by specific high-cost medications, complex procedures, and advanced diagnostics. Key categories include biologics for inflammatory bowel disease (IBD), hepatitis C direct-acting antivirals, and various endoscopic procedures. Understanding these high-volume categories is critical for optimizing PA workflows and ensuring patient access to necessary care.

Common Prior Authorization Triggers in GI

• **IBD Biologics:** TNF inhibitors (adalimumab, infliximab), integrin inhibitors (vedolizumab), IL-12/23 inhibitors (ustekinumab), JAK inhibitors (tofacitinib, upadacitinib), S1P modulators (ozanimod, etrasimod), and risankizumab [src: acg-guidelines, aga-guidelines].
• **Hepatitis C Direct-Acting Antivirals (DAAs):** Sofosbuvir-velpatasvir, glecaprevir-pibrentasvir, with pathways differing for treatment-naive vs. treatment-experienced patients [src: aasld-guidelines].
• **Advanced Imaging:** MRCP, MR enterography, CT enterography for IBD assessment, and other advanced abdominal imaging.
• **Endoscopic Procedures:** Capsule endoscopy (CPT 91110), small-bowel enteroscopy, ERCP, and EUS for specific diagnostic and therapeutic indications.
• **Specialty Drugs for Functional GI Disorders:** Eluxadoline, prucalopride, linaclotide, and plecanatide.
• **Non-Routine Colonoscopy:** High-risk surveillance or post-polypectomy surveillance may require PA on some plans.

Essential Documentation for GI Prior Authorizations

• **IBD Biologics:** Diagnosis confirmation (endoscopic, imaging, histologic), disease severity (Mayo score for UC, CDAI/Harvey-Bradshaw for Crohn's), prior conventional-therapy trial, prior biologic experience, TB/hepatitis screening, step therapy compliance [src: acg-guidelines, aga-guidelines].
• **Hep C DAAs:** Genotype, fibrosis stage (FibroSure, transient elastography, biopsy), prior-treatment history, coinfections (HIV, HBV), drug-drug interaction review [src: aasld-guidelines].
• **Advanced Imaging:** Clinical question, prior imaging history, conservative-evaluation workup completion.
• **Capsule Endoscopy:** Prior workup including upper GI series or EGD, indication (obscure GI bleeding, IBD evaluation, polyp surveillance), payer-specific medical necessity criteria.

Common Prior Authorization Denial Reasons in Gastroenterology

• **Step Therapy Non-Compliance:** Payer requires failure of conventional therapy (e.g., 5-ASA for UC, immunomodulators for moderate-severe IBD) or specific biologic sequencing before approval [src: acg-guidelines, aga-guidelines].
• **Biosimilar Substitution:** Denial of brand TNF inhibitor when a biosimilar is mandated as first-line therapy.
• **Inadequate Disease Severity Documentation:** Missing Mayo score, CDAI, or equivalent severity measure for IBD biologics.
• **Screening Gaps:** Lack of documented TB or hepatitis screening prior to biologic initiation.
• **Hep C DAA Misclassification:** Errors in fibrosis-stage documentation or treatment-naive vs. treatment-experienced status [src: aasld-guidelines].
• **Inappropriate Imaging Criteria:** Insufficient clinical correlation for advanced imaging requests like MR enterography.
• **Capsule Endoscopy:** Prior workup deemed insufficient or indication not meeting payer policy.

Navigating Unique GI Prior Authorization Workflows

Gastroenterology practices encounter several workflow constraints unique to the specialty. These include the ongoing burden of chronic treatment re-authorizations for IBD biologics, the variability in biosimilar substitution policies across payers, and the critical distinction between treatment-naive and treatment-experienced classifications for both IBD and Hepatitis C therapies. Additionally, the split between medical and pharmacy benefits for biologics and cyclic diagnostic procedure PA cycles add layers of complexity.

How Klivira Streamlines Gastroenterology Prior Authorization

• **Guideline-Aware Step Therapy Logic:** Incorporates ACG/AGA-guideline-aware step therapy logic for IBD biologic sequencing, minimizing denials [src: acg-guidelines, aga-guidelines].
• **Automated Treatment-Status Classification:** Automatically classifies treatment-naive vs. treatment-experienced status from EMR medication history for IBD biologics and Hep C DAAs.
• **Hep C DAA Workflow Support:** Comprehensive workflow for genotype, fibrosis stage, and drug-interaction documentation, aligning with AASLD guidelines [src: aasld-guidelines].
• **Periodic Re-authorization Management:** Manages periodic re-authorization workflows for chronic-treatment IBD biologics, ensuring continuous coverage.
• **Medical-vs-Pharmacy Benefit Routing:** Intelligently routes prior authorizations based on medical-vs-pharmacy benefit for biologic agents, adapting to administration mode changes.